Fatty liver medical therapy: Difference between revisions
No edit summary |
|||
| Line 11: | Line 11: | ||
==Medical Therapy== | ==Medical Therapy== | ||
[[Clinical practice guideline]]s direct treatment. | |||
Per the American Gastroenterological Association (AGA) in 2021<ref name="pmid34602251">{{cite journal| author=Kanwal F, Shubrook JH, Adams LA, Pfotenhauer K, Wai-Sun Wong V, Wright E | display-authors=etal| title=Clinical Care Pathway for the Risk Stratification and Management of Patients With Nonalcoholic Fatty Liver Disease. | journal=Gastroenterology | year= 2021 | volume= 161 | issue= 5 | pages= 1657-1669 | pmid=34602251 | doi=10.1053/j.gastro.2021.07.049 | pmc=8819923 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=34602251 }} </ref>, per Figure 3 notes, treatment may include: | |||
* "Patients with T2DM may benefit from some diabetes medications, such as pioglitazone and some GLP-1 RAs that have reported histological improvement in RCTs in patients with NASH, either with or without diabetes. Among GLP-1 RAs, semaglutide has the strongest evidence of liver histological benefit." | |||
* "Vitamin E improves steatohepatitis in patients with NASH without diabetes, with less evidence in patients with T2D." | |||
Per the American Association for the Study of Liver Diseases (AASLD) in 2023<ref name="pmid36727674">{{cite journal| author=Rinella ME, Neuschwander-Tetri BA, Siddiqui MS, Abdelmalek MF, Caldwell S, Barb D | display-authors=etal| title=AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease. | journal=Hepatology | year= 2023 | volume= | issue= | pages= | pmid=36727674 | doi=10.1097/HEP.0000000000000323 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=36727674 }} </ref>: | |||
* "Semaglutide can be considered for its approved indications (T2DM/obesity) in patients with NASH, as it confers a cardiovascular benefit and improves NASH." | |||
* "Pioglitazone improves NASH and can be considered for patients with NASH in the context of patients with T2DM." | |||
* "Vitamin E can be considered in select individuals as it improves NASH in some patients without diabetes." | |||
"Available data on semaglutide, pioglitazone, and vitamin E do not demonstrate an antifibrotic benefit, and none has been carefully studied in patients with cirrhosis." | |||
==References== | ==References== | ||
Revision as of 16:58, 17 April 2023
|
Fatty Liver Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Fatty liver medical therapy On the Web |
|
American Roentgen Ray Society Images of Fatty liver medical therapy |
|
Risk calculators and risk factors for Fatty liver medical therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:
Please help WikiDoc by adding more content here. It's easy! Click here to learn about editing.
Overview
The treatment of fatty liver depends on what is causing it, and generally, treating the underlying cause will reverse the process of steatosis if implemented at early stage. Recent studies suggest that diet, exercise, and especially antiglycemic drugs may alter the course of the disease. A randomized controlled trial found that pioglitazone led to metabolic and histologic improvement in subjects with nonalcoholic steatohepatitis.[1]
Elderly may not benefit from treatment[2].
Medical Therapy
Clinical practice guidelines direct treatment.
Per the American Gastroenterological Association (AGA) in 2021[3], per Figure 3 notes, treatment may include:
- "Patients with T2DM may benefit from some diabetes medications, such as pioglitazone and some GLP-1 RAs that have reported histological improvement in RCTs in patients with NASH, either with or without diabetes. Among GLP-1 RAs, semaglutide has the strongest evidence of liver histological benefit."
- "Vitamin E improves steatohepatitis in patients with NASH without diabetes, with less evidence in patients with T2D."
Per the American Association for the Study of Liver Diseases (AASLD) in 2023[4]:
- "Semaglutide can be considered for its approved indications (T2DM/obesity) in patients with NASH, as it confers a cardiovascular benefit and improves NASH."
- "Pioglitazone improves NASH and can be considered for patients with NASH in the context of patients with T2DM."
- "Vitamin E can be considered in select individuals as it improves NASH in some patients without diabetes."
"Available data on semaglutide, pioglitazone, and vitamin E do not demonstrate an antifibrotic benefit, and none has been carefully studied in patients with cirrhosis."
References
- ↑ Belfort R, Harrison SA, Brown K; et al. (2006). "A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis". N. Engl. J. Med. 355 (22): 2297–307. doi:10.1056/NEJMoa060326. PMID 17135584.
- ↑ van Kleef LA, Sonneveld MJ, Kavousi M, Ikram MA, de Man RA, de Knegt RJ (2022). "Fatty liver disease is not associated with increased mortality in the elderly: A prospective cohort study". Hepatology. doi:10.1002/hep.32635. PMID 35753042 Check
|pmid=value (help). - ↑ Kanwal F, Shubrook JH, Adams LA, Pfotenhauer K, Wai-Sun Wong V, Wright E; et al. (2021). "Clinical Care Pathway for the Risk Stratification and Management of Patients With Nonalcoholic Fatty Liver Disease". Gastroenterology. 161 (5): 1657–1669. doi:10.1053/j.gastro.2021.07.049. PMC 8819923 Check
|pmc=value (help). PMID 34602251 Check|pmid=value (help). - ↑ Rinella ME, Neuschwander-Tetri BA, Siddiqui MS, Abdelmalek MF, Caldwell S, Barb D; et al. (2023). "AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease". Hepatology. doi:10.1097/HEP.0000000000000323. PMID 36727674 Check
|pmid=value (help).